MA37649B1 - Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées - Google Patents

Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Info

Publication number
MA37649B1
MA37649B1 MA37649A MA37649A MA37649B1 MA 37649 B1 MA37649 B1 MA 37649B1 MA 37649 A MA37649 A MA 37649A MA 37649 A MA37649 A MA 37649A MA 37649 B1 MA37649 B1 MA 37649B1
Authority
MA
Morocco
Prior art keywords
producing hydroxylated
compounds
cyclopenta
cyclopentylpyrimidine compounds
hydroxylated cyclopentylpyrimidine
Prior art date
Application number
MA37649A
Other languages
English (en)
French (fr)
Other versions
MA37649A1 (fr
Inventor
Travis Remarchuk
Jonathan W Lane
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA37649A1 publication Critical patent/MA37649A1/fr
Publication of MA37649B1 publication Critical patent/MA37649B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA37649A 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées MA37649B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
MA37649A1 MA37649A1 (fr) 2016-06-30
MA37649B1 true MA37649B1 (fr) 2017-03-31

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37649A MA37649B1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Country Status (18)

Country Link
US (1) US9309204B2 (https=)
EP (1) EP2861583B1 (https=)
JP (1) JP6214636B2 (https=)
KR (1) KR20150020211A (https=)
CN (1) CN104487430B (https=)
AU (1) AU2013262568B2 (https=)
BR (1) BR112014028570A2 (https=)
CA (1) CA2873653A1 (https=)
DK (1) DK2861583T3 (https=)
ES (1) ES2588878T3 (https=)
IL (1) IL235714A0 (https=)
MA (1) MA37649B1 (https=)
MX (1) MX2014013865A (https=)
PL (1) PL2861583T3 (https=)
RU (1) RU2014151017A (https=)
SG (1) SG11201407613RA (https=)
SI (1) SI2861583T1 (https=)
WO (1) WO2013173736A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SI3068770T1 (sl) 2013-11-15 2020-02-28 F. Hoffmann-La Roche Ag Postopki za pripravo pirimidinilciklopentanskih spojin
KR102284938B1 (ko) * 2013-11-27 2021-08-02 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
RU2732404C2 (ru) * 2014-09-26 2020-09-16 Ф. Хоффманн-Ля Рош Аг СПОСОБЫ ПОЛУЧЕНИЯ (ЦИКЛОПЕНТИЛ[d]ПИРИМИДИН-4-ИЛ)ПИПЕРАЗИНОВЫХ СОЕДИНЕНИЙ
CN115916758A (zh) 2020-06-16 2023-04-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3386600A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE60020560T2 (de) * 1999-06-03 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. Substituierte pyrazol-derivate
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法

Also Published As

Publication number Publication date
WO2013173736A1 (en) 2013-11-21
JP2015518837A (ja) 2015-07-06
ES2588878T3 (es) 2016-11-07
SI2861583T1 (sl) 2016-10-28
EP2861583A1 (en) 2015-04-22
CA2873653A1 (en) 2013-11-21
KR20150020211A (ko) 2015-02-25
CN104487430A (zh) 2015-04-01
BR112014028570A2 (pt) 2018-04-24
AU2013262568A1 (en) 2015-01-22
MX2014013865A (es) 2015-05-07
SG11201407613RA (en) 2015-01-29
US9309204B2 (en) 2016-04-12
RU2014151017A (ru) 2016-07-10
PL2861583T3 (pl) 2016-12-30
IL235714A0 (en) 2015-02-01
HK1208673A1 (en) 2016-03-11
DK2861583T3 (en) 2016-10-03
US20150099881A1 (en) 2015-04-09
CN104487430B (zh) 2016-08-24
AU2013262568B2 (en) 2017-08-31
EP2861583B1 (en) 2016-06-29
JP6214636B2 (ja) 2017-10-18
MA37649A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
MA37649A1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
JOP20190230A1 (ar) طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MY196260A (en) Small Molecule Inhibitors of the Jak Family Of Kinases
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MY161416A (en) 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MY200590A (en) Compounds useful as kinase inhibitors
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
AU2016320892A8 (en) Salts of a Pim kinase inhibitor
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases